Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine MBT (Validive) for prevention of severe oral mucositis in oropharyngeal cancer
NCT04648020Phase 3Terminated
- Sponsor
- Monopar Therapeutics Inc.
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 5
01
Overview
A Phase 3 trial of Clonidine Lauriad in oral mucositis (OM), sponsored by Monopar Therapeutics Inc.. Started Feb 2021; status: terminated.
02
Drugs
Clonidine Lauriad
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT04648020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648020.